Gentium S.p.a. Revenue Growth Rates (GENT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Gentium S.p.a.  (GENT)
 

GENT's Revenue Growth by Quarter and Year

Gentium S.p.a.'s Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GENT Revenue (in millions $) FY 2013 FY 2012 FY 2011 FY 2010
4th Quarter December 57.00
3rd Quarter September 0.00
2nd Quarter June 10.23
1st Quarter March 0.00
FY 67.23





GENT Revenue fourth quarter 2013 Y/Y Growth Comment
Gentium S.p.a. reported Revenue rise of 52.65% year on year in the fourth quarter 2013, to $ 57.00 millions, this is lower than Gentium S.p.a.'s recent average Revenue rise of 89.23%.

Looking into fourth quarter 2013 results within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Revenue growth. While Gentium S.p.a.' s Revenue jump of 52.65% ranks overall at the positon no. 121 in the fourth quarter 2013.


GENT Revenue ( Y/Y Growth %) 2013
 2012 2011 2010
4th Quarter December 52.65 % - - -
3rd Quarter September - - - -
2nd Quarter June -69.25 % - - -
1st Quarter March - - - -
FY   -26.3 % - - -

Financial Statements
Gentium S.p.a.'s fourth quarter 2013 Revenue $ 57.00 millions GENT's Income Statement
Gentium S.p.a.'s fourth quarter 2012 Revenue $ 37.34 millions Quarterly GENT's Income Statement


GENT Revenue (Quarter on Quarter Growth %)

 2013
 2012 2011 2010
4th Quarter December - 241.63 % - -
3rd Quarter September - -67.15 % - -
2nd Quarter June - 243.7 % - -
1st Quarter March - - - -
FY (Year on Year)   -26.3 % - - -


Back to GENT Growth rate Comparisons >> Back to GENT Growth rate Comparisons >>


Revenue fourth quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #32
Overall #121

Revenue Y/Y Growth Statistics
High Average Low
163.53 % 89.23 % 14.93 %
(Dec 31 2012)   (Dec 31 2013)
Revenue fourth quarter 2013 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #32
Overall #121
Revenue Y/Y Growth Statistics
High Average Low
163.53 % 89.23 % 14.93 %
(Dec 31 2012)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2010, 2011, 2012, 2013

Gentium S.p.a.'s Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GENT's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GENT's IV. Quarter Q/Q Revenue Comment


Gentium S.p.a.'s 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Dec 31 2013)		 12 Months Ending
(Dec 31 2012)		 12 Months Ending
 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 42.92 $ 37.34 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 14.93 % 163.53 % - - -
Year on Year Revenue Growth Overall Ranking # 121 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 14.93 % 163.53 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 121 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2013 period, Gentium S.p.a.'s cumulative twelve months Revenue were $ 43 millions, company would post below average annual Revenue growth of 163.53% year on year, if the fiscal year would end at Dec 31 2013.
A slow-down in the Gentium S.p.a.'s Revenue growth from the 0% growth in Dec 31 2012.

Within the Healthcare sector 31 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 121.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 7
Healthcare Sector # 32
Overall # 121

Revenue TTM Y/Y Growth Statistics
High Average Low
163.53 %
 89.23 %
14.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 32
S&P 500 # 121
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Dec 31 2013 period, Gentium S.p.a.'s cumulative twelve months Revenue were $ 43 millions, company would post below average annual Revenue growth of 14.93% year on year, if the fiscal year would end at Dec 31 2013.
A slow-down in the Gentium S.p.a.'s Revenue growth from the 0% growth in Dec 31 2012.

Within the Healthcare sector 31 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 121.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 7
Healthcare Sector # 32
Overall # 121

Revenue TTM Y/Y Growth Statistics
High Average Low
163.53 %
89.23 %
14.93 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 7
Sector # 32
S&P 500 # 121




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GENT's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Dec 31 2013 within Healthcare SectorY/Y Change %Revenue for the quarter ending Dec 31 2013
Novavax inc 91.55%$ 91.548 millions
Beam Therapeutics Inc 88.18%$ 88.182 millions
Allergan plc84.17%$ 84.174 millions
Lannett Company Inc84.13%$ 84.132 millions
Fonar Corporation83.18%$ 83.179 millions
Wearable Health Solutions, Inc.82.45%$ 82.450 millions
Statera Biopharma Inc fka Cytocom Inc 79.12%$ 79.118 millions
Vaxart Inc 78.12%$ 78.124 millions
Vyant Bio Inc 72.40%$ 72.399 millions
Mimedx Group Inc 71.21%$ 71.212 millions
Xoma Royalty Corporation69.60%$ 69.598 millions
Regulus Therapeutics Inc 68.44%$ 68.437 millions
Endonovo Therapeutics Inc 68.38%$ 68.382 millions
Nuo Therapeutics, Inc.64.73%$ 64.734 millions
Pressure Biosciences Inc 63.89%$ 63.889 millions
Achari Ventures Holdings Corp I62.93%$ 62.927 millions
Dynavax Technologies Corporation57.64%$ 57.641 millions
Lineage Cell Therapeutics Inc 56.73%$ 56.733 millions
Nanostring Technologies Inc 55.86%$ 55.860 millions
Pacific Biosciences Of California Inc 55.39%$ 55.393 millions
Dexcom Inc 55.26%$ 55.255 millions
Veracyte Inc 53.42%$ 53.422 millions
Inovio Pharmaceuticals Inc 53.31%$ 53.308 millions
Assertio Holdings inc 52.72%$ 52.719 millions
Gentium S.p.a.52.64%$ 52.644 millions
Concord Medical Services Holdings Ltd52.37%$ 52.368 millions
Macrogenics Inc 52.12%$ 52.118 millions
Bolt Biotherapeutics Inc 50.90%$ 50.895 millions
Alnylam Pharmaceuticals Inc 49.85%$ 49.853 millions
Delcath Systems Inc 48.26%$ 48.259 millions


About Gentium S.p.a. Revenue Growth Rates (GENT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.